Publications by authors named "Kazuyo Miyagi"
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are linked to better survival rates in cancer patients, particularly those experiencing immune-related adverse events (irAEs).
- A study analyzed 200 patients with non-small-cell lung cancer, gastric cancer, and melanoma, finding that those with irAEs had improved overall survival (OS) and progression-free survival (PFS) compared to those without.
- Factors such as age, albumin levels, and smoking history were associated with a higher risk of developing irAEs, which were mostly mild (grade ≤2), and common irAEs included pneumonitis and thyroiditis.
Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients.
Cancer Chemother Pharmacol
September 2017
Purpose: Irinotecan (CPT-11) is used to treat advanced colorectal cancer. The drug is activated by carboxylesterases and rendered inactive by CYP3A4. Recently, the efficacy of combining CPT-11 and anti-epidermal growth factor receptor (EGFR) agents was confirmed in patients with KRAS wild-type metastatic colorectal cancer.
View Article and Find Full Text PDF